RX for Africa Inc. and Zirus Inc. have entered into a letter of intent to form ZiRx Therapeutics Ltd., a joint venture that will utilize the anti-viral discovery platform of Zirus Inc. to target host cell proteins with drugs that potentially block or stop the spread of infectious diseases in completely new ways. Targeting host proteins may lead to broad spectrum antiviral drugs as well as drugs that are less susceptible to viral resistance. The joint venture will include as many as 25 specifically identified drugs with positive preliminary antiviral data that have been approved in a major territory or are in a Phase III trial in a major territory for a different indication. The strategy is for these target drugs to be 'repurposed' against infectious disease (such as the H1N1 swine flu virus) and brought on the market quickly in Ethiopia through Rx for Africa's Ethiopian manufacturing and distribution capabilities. These drugs can then be produced inexpensively to sell throughout Africa and other available global markets. The joint venture is subject to final due diligence and respective board approvals of a definitive agreement.

To discuss the joint venture to form ZiRx Therapeutics, Ltd.

Rx for Africa Inc. announced the signing of a letter of intent for a strategic alliance with Rusan Pharma Ltd. of Mumbai, India. The alliance commences immediately, with Rusan providing Rx for Africa Inc. the tuberculosis (TB) drug, 'RUCOX-4' (four drug combination) as per the recommended dosage form of the World Health Organization (WHO), which is also approved by the Ethiopian Ministry of Health and already marketed in some CIS & African countries. Per capita the highest number of deaths and the highest mortality from TB in the world are in Sub-Saharan Africa. In addition, the agreement also maps out a strategy in which Rx Africa (Ethiopia) PLC will market Rusan Pharma's 202 drugs in Ethiopia, and other sub-Saharan African countries. Importantly, Rusan will assist Rx in developing anti-malarials and HIV medications for these markets, and will assist us to start manufacturing their whole list of drugs in Ethiopian facilities.